Figure 1 Contribution of the gut microbiota

Slides:

Advertisements

Similar presentations

yuna Jo Nature.Nature Jul 4;499(7456): doi: /nature Epub 2013 Jun 26.

Advertisements

The Role of Gut Microbiota in Non-alcoholic Fatty Liver Disease

Relationship with Bile acids and Microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Neutrophils in liver inflammation

Figure 5 Dendritic cells in liver inflammation

The inflammasome in liver disease

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 1 Gut microorganisms at the intersection of several diseases

Lymphotoxins: New Targets for Hepatocellular Carcinoma

Figure 2 The microbiome–gut–brain axis

Figure 7 Clinical options for HCC therapy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immune mechanisms in liver homeostasis

Figure 2 Signalling molecules and pathways involved in HSC activation

The Multifaceted Role of the Intestinal Microbiota in Colon Cancer

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 The 'leaky gut' hypothesis

Gallstone Disease and Cancer Risk: Finding the Bug in the System

Figure 4 Tumour-induced neutrophil extracellular trap

Gut microbiota and non-alcoholic fatty liver disease: new insights

David R. Meldrum, M. D. , Marge A. Morris, M. Ed. , R. D. , C. D. E

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 An overview of the TIMER microbiota–host

Figure 3 The mechanism of injury in ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Targeting the gut-liver axis in liver disease

Figure 4 Macrophages in liver inflammation

Figure 5 Hepatic regeneration in ACLF

Figure 3 Serotonin influences many peripheral tissues

The Intestinal Immune System in Obesity and Insulin Resistance

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Targeting gut flora to prevent progression of hepatocellular carcinoma

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Figure 2 Schematic of normal and abnormal liver regeneration

Nitin Raj, Laura D. Attardi Current Biology

Figure 4 The gut–liver relationship in PSC

Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.

Figure 3 Strategies to improve liver regeneration

The National Biome Initiative: An allergy perspective

Figure 1 Regulation of hepatic glucose metabolism by the gut, brain and liver Figure 1 | Regulation of hepatic glucose metabolism by the gut, brain and.

Figure 7 T cells in liver inflammation

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

The Origins and Drivers of Insulin Resistance

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Microbiota-related pathways in atherosclerosis

Microbiome and Anticancer Immunosurveillance

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

David R. Meldrum, M. D. , Marge A. Morris, M. Ed. , R. D. , C. D. E

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Bile acid-induced hepatic inflammation and carcinogenesis

Volume 61, Issue 1, Pages S79-S90 (November 2014)

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma

Macrophage heterogeneity in liver injury and fibrosis

Figure 2 Initiators of obesity-associated inflammation in adipocytes

Microbiome as a therapeutic target in alcohol-related liver disease

Sander Lefere, Frank Tacke JHEP Reports

Presentation transcript:

Figure 1 Contribution of the gut microbiota to hepatocarcinogenesis: mechanisms and therapeutic targets Figure 1 | Contribution of the gut microbiota to hepatocarcinogenesis: mechanisms and therapeutic targets. Dysbiosis and the leaky gut promote the progression of liver disease and the development of hepatocellular carcinoma (HCC) via multiple mechanisms, including the release of cancer-promoting and senescence-promoting metabolites such as deoxycholic acid (DCA) from the dysbiotic microbiota, and increased hepatic exposure to gut-derived microbiota-associated molecular patterns (MAMPs) such as lipopolysaccharide (LPS), which in turn promote hepatic inflammation, fibrosis, proliferation and the activation of anti-apoptotic signals. These cancer-promoting signalling pathways can be interrupted at several levels: using probiotics to restore eubiosis; using antibiotics to eliminate disease-promoting bacteria and decrease the release of MAMPs and metabolites from the leaky gut; using agents to improve the gut barrier; and potentially using inhibitors of bacterial metabolism to reduce the production of cancer-promoting metabolites by the gut microbiota. FXR, farnesoid X receptor; HSC, hepatic stellate cell; TLR, Toll-like receptor; SASP, senescence-associated secretory phenotype. Yu, L.-X. & Schwabe, R. F. (2017) The gut microbiome and liver cancer: mechanisms and clinical translation Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.72